Danish pharma large Novo Nordisk (NVO) will make a major funding of roughly $1.2 billion to assemble a brand new manufacturing facility in Odense, Denmark.
The brand new facility will deal with the manufacturing of medicines used for uncommon illnesses, together with remedies for situations like haemophilia. The ability can be